Acute Medium Chain Triglycerides (MCT) Intake in Young and Older Participants (Opti-MCT)

March 24, 2020 updated by: Université de Sherbrooke

Optimisation of Acute Medium Chain Triglycerides Intake Characteristics on Different Plasma Metabolites in Young and Older Participants

Compare plasma metabolites following different conditions paired with a dietary MCT beverage over an 8-hour metabolic day protocol in young and older participants.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Study Type

Interventional

Enrollment (Actual)

20

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Canada
    • Quebec
      • Sherbrooke, Quebec, Canada, J1H4C4
        • Rearsh Centre on Aging

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

20 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

Yes

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • 10 health young (20-40 y old) and 10 health older (> 60 y old) participants
  • Men and women

Exclusion Criteria:

  • smoking
  • diabetes (fasting glucose >7.0 mmol/l and glycated hemoglobin >6.9%)
  • strenuous aerobic exercise more than three times a week
  • untreated hypertension, dyslipidemia, and abnormal renal, liver, heart or thyroid function
  • under medication known to affect triglycerides and carbohydrates metabolism (i.e. diuretics, beta-blockers, steroids, insulin sensitizing)

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Basic Science
  • Allocation: Non-Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: MCT intake in young participants

Different conditions paired with a dietary MCT beverage over an 8-hour metabolic day protocol in young participants.

Interventions:

  1. No MCT intake with breakfast, no lunch (i.e. CTL)
  2. No MCT intake with lunch, no breakfast (i.e CTL inverted)
  3. 10g of Betaquik with breakfast, no lunch (i.e BQ10)
  4. 20g of Betaquik with breakfast, no lunch (i.e BQ20)
  5. 10g of Betaquik with low-carbs breakfast, no lunch (i.e BQ10LC)
  6. 10g of Betaquik with lunch, no breakfast (i.e BQ10 inverted)
Dietary supplement: No MCT intake with breakfast, no lunch
Water given with a regular standardize breakfast and water given at noon without lunch.
Other Names:
  • CTL
Dietary supplement: No MCT intake with lunch, no breakfast
Water given in the beginning of the metabolic study day without breakfast and water given at noon with a regular standardize lunch.
Other Names:
  • CTL inverted
Dietary supplement: 10g of Betaquik
BQ10 given with a regular standardize breakfast and BQ10 given at noon without lunch.
Other Names:
  • BQ10
Dietary supplement: 10g of Betaquik with low-carbs breakfast
BQ10 given with a low-carbs standardize breakfast and BQ10 given at noon without lunch.
Other Names:
  • BQ10LC
Dietary supplement: 20g of Betaquik
BQ20 given with a regular standardize breakfast and BQ20 given at noon without lunch.
Other Names:
  • BQ20
Dietary supplement: 10g of Betaquik with lunch, no breakfast
BQ10 given in the beginning of the metabolic study day without breakfast and BQ10 given at noon with a regular standardize lunch.
Other Names:
  • BQ10 inverted
Experimental: MCT intake in older participants

Different conditions paired with a dietary MCT beverage over an 8-hour metabolic day protocol in older participants.

Interventions:

  1. No MCT intake with breakfast, no lunch (i.e. CTL)
  2. No MCT intake with lunch, no breakfast (i.e CTL inverted)
  3. 10g of Betaquik with breakfast, no lunch (i.e BQ10)
  4. 20g of Betaquik with breakfast, no lunch (i.e BQ20)
  5. 10g of Betaquik with low-carbs breakfast, no lunch (i.e BQ10LC)
  6. 10g of Betaquik with lunch, no breakfast (i.e BQ10 inverted)
Dietary supplement: 10g of Betaquik
BQ10 given with a regular standardize breakfast and BQ10 given at noon without lunch.
Other Names:
  • BQ10

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Concentration of plasma ketones (acetoacetate and B-hydroxybutyrate)
Time Frame: 8 hours
To compare acute ketonemia following different conditions paired with a dietary MCT beverage over an 8-hour metabolic day protocol.
8 hours

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Concentration of plasma glucose
Time Frame: 8 hours
To compare acute glucose following different conditions paired with a dietary MCT beverage over an 8-hour metabolic day protocol.
8 hours
Concentration of plasma insulin
Time Frame: 8 hours
To compare acute insulin following different conditions paired with a dietary MCT beverage over an 8-hour metabolic day protocol.
8 hours
Concentration of plasma free fatty acids
Time Frame: 8 hours
To compare acute free fatty acids following different conditions paired with a dietary MCT beverage over an 8-hour metabolic day protocol.
8 hours

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Université de Sherbrooke

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

June 2, 2017

Primary Completion (Actual)

June 25, 2019

Study Completion (Actual)

June 25, 2019

Study Registration Dates

First Submitted

February 1, 2019

First Submitted That Met QC Criteria

February 4, 2019

First Posted (Actual)

February 5, 2019

Study Record Updates

Last Update Posted (Actual)

March 25, 2020

Last Update Submitted That Met QC Criteria

March 24, 2020

Last Verified

March 1, 2020

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 2017-714

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Ketonemia

Clinical Trials on No MCT intake with breakfast, no lunch

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Australia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe